AUTL (Autolus Therapeutics) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AUTL Autolus Therapeutics PLC AUTL
68 GF Score
Price $2.07
GF Value $21.93
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Autolus Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

AUTL
68GF Score
Autolus Therapeutics PLC AUTL
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Autolus Therapeutics (AUTL) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of $2.07 is trading 90.6% below its estimated GF Value™ of $21.93. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for AUTL:

  • Interest Expense (Positive):
  • GF Value™: $21.93 vs. price of $2.07 (90.6% below fair value)
  • GF Score™: 68/100 with 9 warning signs

No single metric tells the full story. See the AUTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges 6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score

Get the complete analysis for AUTL

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price
$21.93
GF Value